AbbVie (ABBV) Stock
Key stats
- Market cap
- $521.41B
- Price / Earnings ratio
- 50.2x
- EPS (TTM)
- $5.83
- Volume
- Loading
- 52-week high
- $302.93
- 52-week low
- $190.75
- Dividend yield
- 2.35%
- Dividend amount (latest)
- $1.73
- EPS vs analyst estimate
- +4.5%Q3 FY25 · $1.86 vs $1.78
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with ABBV
Recent news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
ABBV

AbbVie expands Oxford R&D facility as part of £120 million-plus investment
AbbVie expands Oxford R&D facility as part of £120 million-plus investment
ABBV

AbbVie Hit a New High After Earnings. There's More Upside Left.
AbbVie Hit a New High After Earnings. There's More Upside Left.
ABBV

AbbVie Director Jennifer Davis Resigns From Board
AbbVie Director Jennifer Davis Resigns From Board
ABBV
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 62.83
- MACD 12/26/9
- 5.50
- EMA 9 of MACD
- 5.72
- MACD histogram
- -0.23
- SMA 50
- $274.15
- Price above SMA 50
- EMA 50
- $276.89
- Price above EMA 50
- SMA 200
- $240.04
- Price above SMA 200
- EMA 200
- $246.96
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 14 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $3.66 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
ABBV

AbbVie expands Oxford R&D facility as part of £120 million-plus investment
AbbVie expands Oxford R&D facility as part of £120 million-plus investment
ABBV

AbbVie Hit a New High After Earnings. There's More Upside Left.
AbbVie Hit a New High After Earnings. There's More Upside Left.
ABBV

AbbVie Director Jennifer Davis Resigns From Board
AbbVie Director Jennifer Davis Resigns From Board
ABBV

AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test
AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test
ABBV

The Best Dividend Stocks to Buy With $5,000 in November
The Best Dividend Stocks to Buy With $5,000 in November
ABBV

ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
ABBV

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
ABBV

4 Elite Dividend Stocks That Pay You Passive Income Every Quarter
4 Elite Dividend Stocks That Pay You Passive Income Every Quarter
ABBV

2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever
2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever
ABBV
News tone: automated (AI) classification of the article's content, not a price prediction.
About AbbVie
AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert A. Michael CPA | CEO & Chairman of the Board | 1970 |
| Mr. Scott T. Reents | Executive VP & CFO | 1967 |
| Dr. Azita Saleki Ph.D. | Executive VP & COO | 1963 |
| Dr. Roopal B. Thakkar M.D. | Executive VP of Research & Development and Chief Scientific Officer | 1972 |
| Mr. Jeffrey Ryan Stewart | Executive VP & Chief Commercial Officer | 1969 |
| Ms. Linda Ray | Senior VP & Chief Information Officer | — |
| Ms. Elizabeth Shea | Senior Vice President of Investor Relations | — |
| Mr. Perry C. Siatis | Executive VP, General Counsel & Secretary | 1975 |
| Mr. Demetris D. Crum | Executive VP & Chief Human Resources Officer | 1981 |
| Mr. Wulff-Erik von Borcke | Senior VP & President of Oncology | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 62.83
- MACD 12/26/9
- 5.50
- EMA 9 of MACD
- 5.72
- MACD histogram
- -0.23
- SMA 50
- $274.15
- Price above SMA 50
- EMA 50
- $276.89
- Price above EMA 50
- SMA 200
- $240.04
- Price above SMA 200
- EMA 200
- $246.96
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
14 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $294.00
- Average
- $319.67
- High
- $346.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.3 | +16.8 | ||||||||||
| 2022 | +1.1 | +7.9 | +9.8 | -9.7 | -0.3 | +4.9 | -6.7 | -4.1 | -3.1 | +5.8 | +9.7 | -0.0 |
| 2023 | -9.0 | +5.0 | +2.6 | -5.8 | -10.2 | +1.0 | +10.8 | -1.1 | +0.6 | -4.8 | -0.1 | +8.1 |
| 2024 | +2.9 | +5.0 | +1.8 | -10.0 | -0.3 | +7.1 | +8.8 | +3.5 | -0.1 | +3.5 | -10.1 | -2.2 |
| 2025 | +2.5 | +9.9 | -0.9 | -5.4 | -3.7 | -0.7 | -0.5 | +7.8 | +9.3 | -10.8 | +7.4 | +1.5 |
| 2026 | -2.7 | +2.9 | -7.2 | -1.7 | +5.4 | +18.2 | -0.0 | +4.6 | +0.6 | +13.4 | +2.1 |



